TABLE 1.

Overview of clinical trials assessing treatments for ovarian cancer patients resistant to PARP inhibitors.

Category	Study name or identifier	Phase	PARPi	Combination	Population	Results	Study status
Replace other PARPis	OReO/ENGOT-Ov38 NCT03106987	IIIb	Olaparib	-	Patients with epithelial ovarian cancer previously treated with a PARPi and responding to repeat platinum chemotherapy	PFS 5.3 months vs. 2.8 months (olaparib group vs. placebo group)	Completed
Antiangiogenic agents	NCT02354131	II	Niraparib	Bevacizumab	Platinum-sensitive recurrent ovarian cancer	PFS 11.9 months vs. 5.5 months (combination group vs. nilaparib alone)	Completed
	EVOLVE	II	Olaparib	Cediranib	Patients with high-grade serous ovarian cancer who relapsed or progressed after PARPi maintenance therapy	16-week PFS rate 55%, 50%, and 39%, respectively (platinum-sensitive group, platinum-resistant group, and progression group after standard chemotherapy)	Completed
Immune checkpoint inhibitors (ICIs)	NCT02657889	I/II	Nilaparib	Pembrolizumab	Patients with recurrent ovarian cancer	ORR was 18% (90% CI, 11%–29%), with a disease control rate of 65% (90% CI, 54%–75%), including three (5%) with confirmed complete responses, eight (13%) with confirmed partial responses, 28 (47%) with stable disease, and 20 (33%) with progressive disease	Completed
	MEDIOLA NCT02734004	I/II	Olaparib	Dulvalumab	Patients with BRCA2-mutated metastatic breast and ovarian cancer	The 28-week disease control rate (DCR) was 65.6%, and the ORR was 71.9%, with 7 patients achieving complete remission (CR)	Recruiting
Cell cycle checkpoint inhibitors	NCT03057145	I	Olaparib	Prexasertib	Advanced solid tumors	Four of 18 BRCA1-mutant patients who were P ARPi-resistant achieved a partial response	Completed